Stauber Performance Ingredients of Fullerton, Calif., a maker of nutritional ingredients and blends, has acquired Pharmline, which also makes nutritional ingredients and is based in Florida, New York. Staubline was acquired last year by the New York-based, middle-market private equity firm ICV Partners. Terms of the deal were not disclosed.
ICV Partners (ICV), a leading investment firm focused on lower middle market companies, announced today that its portfolio company Stauber Performance Ingredients, a manufacturer and distributor of nutritional ingredients and blends, has acquired Pharmline, Inc. in a transaction that will broaden its product lines and its geographic footprint.
Dan Stauber, CEO of Stauber, said, “Pharmline is a highly respected brand that is well recognized in the nutritional industry and its value added processing capabilities, as well as their sales and technical expertise, provide a strong platform for us to pursue new market opportunities on a national scale. We are impressed with the company’s operations and look forward to working with the management team to build on their strong customer relationships.”
Olivier Guiot, Chief Executive Officer of Pharmline, said, “The combination of Stauber and Pharmline is a strong market fit that creates an organization better positioned to provide superior quality products that improve health.”
ICV acquired Stauber in 2011 and has since worked with the company’s management team to achieve strong growth during its first year of ownership.
Ira Moreland, a Managing Director of ICV, said, “This is an important strategic step for Stauber and we are very pleased with the company’s first phase of growth over the past year. This acquisition represents the next step in building a market leading company with a national presence. Pharmline adds a range of synergistic customized services and specialized products that combined with Stauber will benefit our customers in many ways.”
About ICV Partners
Founded in 1998, ICV Partners is a leading private investment firm that supports management leaders of strong companies at the lower end of the middle market. With over $440 million in capital under management, the principals of ICV have crafted a strong track record of helping companies improve performance over the long term, investing across a variety of industries. ICV seeks to make control investments in market leading businesses with $25 million to $250 million in revenue.